Grace Therapeutics annual meeting: directors re-elected, say-on-pay approved

Grace Therapeutics, Inc.

Annual meeting held Sept 17, 2026; 9,973,325 shares present (61.28% of 16,274,026 outstanding).
All five director nominees elected: Kavuru, Davis, Kohli, Kottayil, Neugeboren, each with ~6.0M votes for.
Say-on-pay approved: 5,740,999 for vs 222,775 against (93% support excluding broker non-votes).
KPMG LLP ratified as auditor for FY2027: 9,878,292 for, 63,381 against.
Shareholders favor 1-year frequency for say-on-pay (5,772,652 votes); board adopts annual vote.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.